MORE THAN 150 members!

July 2022

AMCA will be hosting an all day Strategic Planning meeting on Wednesday 27th July. 

The meeting will address some of the key challenges still facing this sector and will bring together more than 30 thought leaders from the medicinal cannabis field to generate potential solutions to take to the new federal government. 

We shall keep you fully informed of progress.

July 2022

AMCA will be lodging a submission to this important inquiry. 

Many thanks to Teresa Nicoletti for leading the work on ensuring that our submission will contain all of the elements vital to ensure that the outcome of this inquiry will make crucial changes to the way our veterans, and their families, are supported during and after their service to Australia. 

We shall keep you fully informed of progress.

Jan 2022

AMCA sent a submission to the  

Legislative Council of Western Australia Select Committee into Cannabis and Hemp.

The role of the Select Committee is to inquire into and report on the potential to amend the current legislation and regulations which apply to cannabis and hemp in Western Australia, with particular reference to —
(a) the current barriers to pharmaceutical and nutraceutical use of cannabinoid products;
(b) medicinal cannabis, its prescription, availability and affordability; and
(c) the potential benefits and risks of permitting industrial hemp for human consumption. 

Teresa Nicoletti ensured that the AMCA submission was comprehensive and reflective of the continuing needs of patients. Teresa and Lucy Haslam were also both interviewed by the WA Select Committee.

Submissions will be confidential until such time as the Select Committee publishes them on its website. 

We shall keep you fully informed of progress.

Nov 2021 

AMCA submitted a response to the Victorian Department of Health's proposal to remove Schedule 8 permit requirements for registered medical practitioners looking to prescribe to Schedule 8 medicinal cannabis for non-drug dependent patients. 

Specifically, the proposal would remove the definition of Schedule 8 cannabis and Schedule 8 tetrahydrocannabinol as special Schedule 8 poisons in the Regulations and thereby remove them from the special Schedule 8 permit requirements under Regulations 10, 11 and 12. 

AMCA strongly supports the proposal to remove Schedule 8 permit requirements for registered medical practitioners who wish to prescribe Schedule 8 medicinal cannabis to non-drug dependent patients. 

Sept 2021 

On 7th September, members of the AMCA had a Zoom meeting with Avi Rebera, the new Assistant Secretary of the Regulatory Engagement, Education & Planning Branch, Regulatory Practice and Support Division | Health Products Regulation Group of the Department of Health. 

Avi replaces George Masri in overseeing the ODC/MCS. Danielle Chifley, Director of the MCS, also joined the call. 

AMCA discussed concerns it had with regard to significant delays in members obtaining licences and / or permits and the economic impact this was causing. 

Specific examples from AMCA members were outlined to Avi and Danielle who gave their commitment to continued improvement of the processes and timelines involved. 

AMCA will continue to meet regularly with Avi and Danielle and members are encouraged to continue to provide examples of concern for which AMCA can provide ongoing support and advocacy.

Apr 2021 

The CDA Express website that sparked an investigation by the TGA earlier this year is currently suspended for "improvements".

Industry concerns about the site were raised and published in the original article by Cannabiz on April 29th. CDA Health had, until then, been a member of AMCA but left the Association soon after AMCA expressed its concerns at the site.

AMCA is committed to respond to complaints about alleged or actual breaches of TGA guidelines and has addressed such breaches by other members and non-member companies. 

But AMCA can only address breaches of TGA guidelines if its members report them, so we encourage you to do so to AMCA or directly to the TGA. Your confidentiality will always be respected. 

Please help us to keep this industry safe and compliant.

Apr 2021 

Frequently asked questions on Schedule 3 cannabidiol:

What is medicinal cannabis?

Medicinal cannabis is any product (flower, oil, etc) that has been derived from the plant Cannabis Sativa.

What is in medicinal cannabis?

Extracts of medicinal cannabis usually contain many hundreds of different types of chemicals. The most important are the cannabinoids and the terpenes.

Which chemical in cannabis is responsible for the “high” effect?

The chemical responsible for the high of cannabis is called delta-9-cannabinol and it is commonly abbreviated as THC. Not all medicinal cannabis products contain THC.

How do I access medicinal cannabis in Australia?

Cannabis is available in Australia via a prescription from your health care provider (medical doctor and in some states a nurse practitioner).

Can any doctor prescribe cannabis?

Currently no. To do so, a doctor must either be an Authorised Prescriber OR apply to the Australian government for approval for you via the Special Access Scheme – B pathway.

Are there some types of cannabis that can be purchased without a prescription?

A medicinal cannabis product that meets Schedule 3 requirements can be purchased in pharmacies without a prescription. To meet the criteria of Schedule 3 they must be 98% cannabidiol (CBD) at a maximum dose of 150 mg per day. It can contain other cannabinoids to make up the other 2% of which no more than 1% can be THC.

Are there any schedule 3 – CBD medicines available in Australia?

Not yet. To be available they must be on the Australian Register of Therapeutic Goods (ARTG) which requires clinical trials data to demonstrate safety and efficacy. No manufacturer has yet been able to supply to data for their product to be in the ARTG as a Schedule 3 medicine.

Apr 2021 

AMCA is behind a new Veterans’ campaign to improve access, especially for those with PTSD not supported by DVA. 

Chair and long-time cannabis campaigner Lucy Haslam spearheaded an initial fact-finding discussion on Tuesday 13th April with support groups, doctors, veterans and legal experts. There was an enthusiastic attendance with more than 25 people on the call. 

This initiative will be a joint project with the Australian chapter of the Society of Cannabis Clinicians (SCCAC) to address the lack of access or funding for veterans. 

Lucy recently joined Cannabiz co-founder, Martin Lane and editor-at-large, Rhys Cohen in the Green Room to discuss the campaign for proper veteran access and plans for this year’s Australian Medicinal Cannabis Symposium (https://www.cannabiz.com.au/the-green-room-the-campaign-for-veteran-access).

The campaign to improve access for veterans-in-need kicked off on 22nd April with a Change.org petition that already has more than 10,000 signatures.

We'll continue to keep our members updated.

With the Royal Commission into Defence and Veteran Suicide. established on 8 July 2021, AMCA continues to work with veteran groups and advocates to ensure that medicinal cannabis is included and recognised by the Commission as a valuable treatment for veterans wo still need improved access and funding.

To read more about the Royal Commission into Defence and Veteran Suicide, click the image above.

The Royal Commissioners, Mr Nick Kaldas APM, the Hon James Douglas QC, and Dr Peggy Brown AO are required to produce an interim report by 11 August 2022 and a final report by 15 June 2023. 

AMCA will be making a submission to the Royal Commission. Submissions are invited until at least end-March 2022.

Apr 2022

The NSW Legislative Council's Standing Committee on Law and Justice opened an inquiry into the Road Transport Amendment (Medicinal Cannabis-Exemptions from Offences) Bill 2021. 

AMCA made a submission to the inquiry before its deadline of 1 May 2022. It is available to our members on our members' only section.